This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of general formula (I)



(I)

in which

A or B in each case independently of one another represent cyano, halogen, hydrogen, hydroxy, aryl or the group $-NO_2$, $-NH_2$, $-NR^3R^4$, $-C_{1-6}$-alkyl-NR^3R^4, $-N(C_{1-6}$-hydroxyalkyl$)_2$, -NH-C(NH)-CH_3, -NH(CO)-R^5, -$NHCOOR^6$, -NR^7-(CO)-NR^8R^9, -NR^7-(CS)-NR^8R^9, -$COOR^5$, -CO-NR^8R^9, -CONH-C_{1-6}-alkyl-COOH, -SO_2-CH_3, 4-bromo-1-methyl-1*H*-pyrazolo-3yl

or represent C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with halogen, hydroxy, cyano or with the group -$COOR^5$, -$CONR^8R^9$, $-NH_2$, -NH-SO_2-CH_3, -NR^8R^9, -NH-(CO)-R^5, -NR^7-(CO)-NR^8R^9, -SO2-NHR^3, -O-(CO)-R^5 or -O-(CO)-C_{1-6}-alkyl-R^5,

X represents an oxygen atom or the group –NH- or -NR^3R^4,

R^1 represents hydrogen, halogen, hydroxymethyl, C_{1-6}-alkyl, cyano or the group –COOH, -COO-iso-propyl, $-NO_2$, -NH-(CO)-$(CH_2)_2$-COOH or -NH-(CO)-$(CH_2)_2$-COO-C_{1-6}-alkyl, whereby the C_{1-6}-alkyl can optionally be substituted in one or more places, in the same way or differently with halogen,

R^2 represents hydrogen or the group –NH-(CO)-aryl or C_{1-6}-alkyl optionally substituted in

one or more places, the same way or differently with cyano, hydroxy, aryl, heteroaryl, C_{3-6}-heterocycloalkylring, which can optionally be interrupted with one or more nitrogen atoms, or substituted with the group $-NR^8R^9$, -NH-(CO)-NR^8R^9, -NH-(CO)-S-C_{1-6}-alkyl, -NH-(CS)-NR^8R^9, –NH-(CO)O-CH_2-phenyl, -NH-(CO)H, -NH(CO)-R^5, -NH(CO)-OR^5, -(CO)-NH-NH_2, -(CO)-NH-CH_2-(CO)-NH_2, -(CO)-NH-C_{1-6}-alkyl, -COOH,



or

whereby the aryl or the heteroaryl can optionally be substituted in one or more

places, the same or differently with halogen, hydroxy, C_{1-6}-alkyl, $-NH_2$, -NH-(CO)-CH_2-NH_2, $-NO_2$, –(CO)-$C(CH_2)$-C_2H_5, -$COOR^6$, -$COOC(CH_3)_3$, or represents C_3-alkinyl,

R^3 or R^4 in each case independently of one another represent hydrogen or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with hydroxy, phenyl or hydroxyphenyl,
or

R^3 and R^4 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the C_{3-6}-heterocycloalkylring can optionally be substituted with C_{1-6}-alkyl, C_{1-6}-alkyl-COOH or C_{1-6}-alkyl-NH_2,

R^5 represents hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{2-6}-alkenyl, C_{3-6}-cycloalkylring, aryl, heteroaryl, the group -(CO)-NH_2 or C_{3-6}-heterocycloalkylring that can optionally be interrupted with one or more nitrogen and/or oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring
and C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkylring, C_{3-6}-heterocycloalkylring defined above, aryl or heteroaryl can optionally be substituted in one or more places, the same way or differently with halogen, hydroxy, C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkylring defined above, aryl, heteroaryl or with the group $-NR^8R^9$, $-NO_2$, -NR^7-(CO)-R^5, -NH(CO)-C_{1-6}-alkyl-NH-(CO)-C_{1-6}-alkyl, -NR^7-(CO)-NR^8R^9, -CO-CH_3, -COOH, -CO-NR^8R^9, -SO_2-aryl, -SH, -S-C_{1-6}-alkyl, -SO_2-NR^8R^9,
whereby aryl itself can optionally be substituted in one or more places, the same way or differently with halogen, hydroxy, C_{1-6}-alkyl or C_{1-6}-alkoxy,

R^6 represents C_{1-6}-alkyl, C_{2-6}-alkenyl or phenyl,
whereby C_{1-6}-alkyl may optionally be substituted with C_{3-6}-heterocycloalkylring

that can optionally be interrupted with one or more nitrogen and/or oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring,

R^7 represents hydrogen or C_{1-6}-alkyl,

R^8or R^9 in each case independently of one another represent hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl, aryl or heteroaryl or the group R^{10},
whereby C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl, aryl or heteroaryl can optionally be substituted in one or more places, the same way or differently with halogen, heteroaryl, hydroxy, C_{1-6}-alkoxy, hydroxy-C_{1-6}-alkoxy or the group –COOH, $-NO_2$, $-NR^8R^9$, $-N(C_{1-6}\text{-alkyl})_2$ or with a C_{3-6}-heterocycloalkylring can optionally be interrupted with one or more nitrogen and/or oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring,
or

R^8 and R^9 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the C_{3-6}-heterocycloalkylring can optionally be substituted in one or more places, the same way or differently with hydroxy or the group $-NR^8R^9$, $-NH(CO)-R^5$, hydroxy-C_{1-6}-alkyl or -COOH and

R^{10} represents $-SO_2$-aryl, $-SO_2$-heteroaryl or $-SO_2-NH_2$ or $-SO_2-C_{1-6}$-alkyl,
whereby the aryl can be substituted with $-C_{1-6}$-alkyl,
with the following provisos:

whereby when X represents $-NR^3R^4$ then R^2 does not represent a substituent,

whereby when A and B represent hydrogen, X represents –NH- and R^2 represents C_{1-6}-alkyl,
then R^1 represents -NH-(CO)-CH(NH_2)-$(CH2)_2$-COOH or -NH-(CO)-CH(NH2)-$(CH_2)_2$-$COOC_2H_5$,

whereby when A represents–(CO)-OC_2H_5 or hydroxy, B represents hydrogen, X represents oxygen, R^1 represents halogen,
then R^2 represents C_3-alkinyl,

whereby when A represents –(CO)-OC_2H_5 or hydroxy, B represents hydrogen, X represents –NH-, R^1 represents $–NO_2$,
then R^2 represents C_3-alkinyl,

whereby when A represents –(CO)-OCH_3,
then X represents oxygen, R^1 represents halogen, R^2 represents C_3-alkinyl and B represenst $-NH_2$, $–NHC_2H_4OH$, $–N(C_2H_4OH)_2$, -NH-(CO)-CH_2-O(CO)CH_3,

whereby when A represents –(CO)-OCH_3,
then X represents –NH-, R^1 represents halogen, R^2 represents $–C_2H_4$-imidazolyl and B represenst hydrogen $-NH_2$,

whereby when A represents $–NHS0_2$-CH_3,
then B represents hydrogen, X represents –NH-, R^1 represents halogen and R^2 represents -C_2H_4-imidazolyl,

whereby when R^1 represents -COO-iso-propyl,
then X represents –NH- and R^2 represents C3-alkinyl and A or B independently of one another represent the group $–NO_2$ or –NH-(CO)-CF_3,

whereby when R^1 represents halogen, X represents –NH-, B represents hydrogen and R^2 represents C_{1-6}-alkyl substituted with $–NH_2$,
then A represents –NH-(CO)-C_6-cycloalkyl-NH_2,

whereby when R^1 represents halogen, X represents –NH-, B represents $–S-CH_3$ and R^2 represents imidazolyl,
then A represents the group



,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

2. (Original) Compounds of general formula (I), according to claim 1

in which

A or B in each case independently of one another represent cyano, halogen, hydrogen, hydroxy, tetrazolyl or the group $-NH_2$, $-NR^3R^4$, $-C_{1-6}$-alkyl-NR^3R^4, -NH-C(NH)-CH_3, -NH(CO)-R^5, -NHCOOR^6, $-NR^7$-(CO)-NR^8R^9, - C_{1-6}-alkyl-COOH, -COOH , $-CONH_2$, -CONH-C_{1-6}-alkyl-COOH,

or represent C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with halogen, hydroxy or with the group -COOH , $-CONR^8R^9$, -NH-SO_2-CH_3 or $-NR^8R^9$,

X represents the group –NH- or $-NR^3R^4$,

R^1 represents cyano, hydrogen, halogen or C_{1-6}-alkyl, whereby the C_{1-6}-alkyl can optionally be substituted in one or more places, in the same way or differently with halogen,

R^2 represents hydrogen or the group –NH-(CO)-aryl or $-C_{1-6}$-alkyl optionally substituted in one or more places, the same way or differently with cyano, hydroxy, aryl , heteroaryl, C_{3-6}-heterocycloalkylring which can be optionally be interrupted in one or more places with one or more nitrogen atoms, or substituted with the group – NR^8R^9, –NH-(CO)-NR^8R^9, -NH-(CO)-S-C_{1-6}-alkyl, -NH-(CS)-NR^8R^9, -NH(CO)-R^5, -NH(CO)-OR^5, -(CO)-NH-NH_2, -(CO)-NH-CH_2-(CO)-NH_2, -(CO)-NH-C_{1-6}-alkyl, -COOH whereby the aryl or the heteroaryl can optionally be substituted in one or more places, the same way or differently with hydroxy, C_{1-6}-alkyl, $-NH_2$, -NH-(CO)-CH_2-NH_2, $-NO_2$, -COOR^6,


,

,

,

,

or

,

R^3 or R^4 in each case independently of one another represent hydrogen, C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with hydroxy, phenyl or hydroxyphenyl,

or

R^3 and R^4 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the

C_{3-6}-heterocycloalkylring can optionally be substituted with C_{1-6}-alkyl, C_{1-6}-alkyl-COOH or C_{1-6}-alkyl-NH2,

R^5 represents hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{2-6}-alkenyl, C_{3-6}-cycloalkylring, heteroaryl , the group -(CO)-NH_2 or C_{3-6}-heterocycloalkylring that can optionally be interrupted with one or more nitrogen and/or oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring
and C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-heterocycloalkylring define above, aryl or heteroaryl can optionally be substituted in one or more places, the same way or differently with halogen, hydroxy, C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkylring define above, aryl, heteroaryl or with the $-NR^8R^9$, $-NO_2$, -NR^7-(CO)-R^5, -NH(CO)-C_{1-6}-alkyl-NH-(CO)-C_{1-6}-alkyl, -NR^7-(CO)-NR^8R^9, -CO-CH_3, -COOH, -CO-NR^8R^9, -SO_2-aryl, -SH, -S-C_{1-6}-alkyl, -SO_2-NR^8R^9, whereby aryl itself can optionally be substituted in one or more places, the same way or differently with halogen or hydroxy, C_{1-6}-alkyl or C_{1-6}-alkoxy,

R^7 represents hydrogen or C_{1-6}-alkyl,

R^8or R^9 in each case independently of one another represent hydrogen, C_{1-6}-alkyl, aryl or heteroaryl or the group R^{10}, whereby C_{1-6}-alkyl, aryl or heteroaryl can optionally be substituted in one or more places, the same way or differently with halogen, heteroaryl, hydroxy, C_{1-6}-alkoxy, hydroxy-C_{1-6}-alkoxy or with the group –COOH, $-NO_2$, or a C_{3-6}-heterocycloalkylring can optionally be interrupted with one or more nitrogen and/or oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring

or

R^8 and R^9 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the

C_{3-6}-heterocycloalkylring can optionally be substituted in one or more places, the same way or differently with hydroxy, hydroxy-C_{1-6}-alkyl or the group $-NR^8R^9$, -NH(CO)-R^5 or -COOH and

R^{10} represents -SO_2-NH_2, -SO_2-C_{1-6}-alkyl, $-SO_2$-aryl, or $-SO_2$-heteroaryl,

whereby the aryl can be substituted with -C_{1-6}-alkyl,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

3. (Currently Amended) Compounds of general formula (I) according to claim 1 ~~or 2~~ in which

A or B in each case independently of one another represent hydrogen, tetrazolyl or the group $-N(CH_3)_2$, -NH-(CO)-pyrrolidinyl, -NH-(CO)-pentyl, -NH-(CO)-hexyl, -NH-(CO)-hexyl-NH_2, -NH-(CO)-C_3H_7, -NH-(CO)-CH_2-phenyl, -NH-(CO)-CH_2-NH_2, -NH-(CO)-C_2H_4-NH_2, -NH-(CO)-$CH(NH_2)$-CH_3, -NH-(CO)-$CH(NH_2)$-hydroxyphenyl, -NH-(CO)-$CH(NH_2)$-CH_2-phenyl, -NH-(CO)-$CH(NH_2)$-CH_2-hydroxyphenyl, -NH-(CO)-CH(NH-(CO)-CH_3)-CH_2-phenyl, -NH-(CO)-CH_2-NH-(CO)-CH_3, -NH-(CO)-$N(C_2H_5)(C_2H_4$-piperidinyl), -NH-(CO)-$N(CH_3)(C_2H_4$-piperidinyl), -NH-(CO)-CH_2-$NH(CH_3)$, -CH_2-$N(CH_3)_2$, -NH-(CO)NH-CH_2-COOH , hydantoinyl, -CH_2-COOH

whereby the pyrrolidinyl can optionally be substituted with hydroxy or the group $-NH_2$, $-N(CH_3)_2$ or -NH-(CO)-CH_3,

and whereby hydantoinyl can be substituted with -CH_3, -CH_2-COOH, or -(CO)-thiazolidinonyl,

X represents or the group -NH-,

R^1 represents halogen and

R^2 represents hydrogen or the group -NH-(CO)-phenyl

or -C_2H_4-, -C_3H_6- both can optionally be substituted in one or more places, the same way or differently with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazolinyl, piperidinyl, $-NH_2$, -NH-CH_2-thienyl, -NH-

pyridinyl-NO_2, -NH-thiazolyl, -SO_2-thienyl, -SO_2-NH_2, -SO_2-CH_3, -SO_2-C_3H_7, pyrrolidinonyl substituted with -COOH, –NH-(CO)-NH-thienyl, –NH-(CO)-NH-phenyl, -NH-(CO)-NH- C_2H_5, -NH-(CO)-$C(CH_3)_3$, -NH-(CO)-S-C_2H_5, -NH-(CS)-NH- C_2H_5, -NH-(CO)-C_2H_5, -NH-(CO)-thienyl, -(CO)-NH-NH_2, -(CO)-NH-CH_2-(CO)-NH_2, -(CO)-NH-C_2H_5, -COOH whereby the phenyl or the imidazolyl, thiazolyl can optionally be substituted in one or more places, the same way or differently with hydroxy, -CH_3, -NH-(CO)-CH_2-NH_2, -$COOC_2H_5$, -$COOC(CH_3)_3$,


,


,


,


,


or


,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or

pharmaceutically acceptable salts thereof.

4. (Currently Amended) Compounds of general formula (I) according to claim 1 ~~any one of claims 1 to 3~~

in which

A or B in each case independently of one another represent hydrogen or the group -NH-(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH2, -NH-(CO)-CH(NH2)- hydroxyphenyl, -NH-(CO)-CH(NH2)-CH2-hydroxyphenyl, hydantoin optionally substituted with –CH3,

X represents or the group –NH-,

R^1 represents halogen and

R^2 represents hydrogen, $-C_2H_4$-imidazolyl or $-C_3H_7$ wich can optionally be substituted in one or more places, the same way or differently with the group -NH-CH_2-thienyl, -NH-(CO)-C_2H_5, -NH-(CO)-$C(CH_3)_3$,


,

,

,

,

or

,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

5. (Original) Compounds of general formula (I) according to claim 4,
N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-

pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[4-[[3-[[(1-aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[4-[[3-[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N^1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,
(4R)-*N*-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]-urea,
N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[2-[[3-[[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[2-[[3-[[(2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N^1-[3-[[5-bromo-2-[[3-[[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- 1,1-cyclopropanedicarboxamide,

N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)-phenyl)-1-pyrrolidinecarboxamide,

N1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,

N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or

N-[3-[[4-[[3-[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide.

6. (Original) Compounds of general formula (I) according to claim 1, in which

A or B in each case independently of one another represent hydrogen or the group $-NO_2$, $-NH_2$, $-NR^3R^4$, $-N(C_{1-6}\text{-hydroxyalkyl})_2$, $-NH(CO)-R^5$, $-NHCOOR^6$, $-NR^7-(CO)-NR^8R^9$, $-NR^7-(CS)-NR^8R^9$, $-COOR^5$, $-CO-NR^8R^9$, $-SO_2-CH_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3yl

or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-NH_2$, $-NH-(CO)-R^5$, $-SO_2-NHR^3$, $-COOR^5$, $-CONR^8R^9$, $-O-(CO)-R^5$, $-O-(CO)-C_{1-6}$-alkyl-R^5,

X represents an oxygen atom or the group –NH-,

R^1 represents hydrogen, halogen, hydroxymethyl or the group –COOH, -COO-iso-propyl, $-NO_2$, $-NH-(CO)-(CH_2)_2-COOH$ or $-NH-(CO)-(CH_2)_2-COO-C_{1-6}$-alkyl,

R^2 represents C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with hydroxy, imidazolyl or the group $-NH_2$, $-NH-(CO)O-CH_2$-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, $-NH-(CO)-CH_2-O$-phenyl, $-NH-(CO)-CH_2$-phenyl, $-NH-(CO)-CH(NH_2)CH_2$-phenyl, $-NH-(CO)-CH_2-CH(CH_3)$-phenyl, -NH-(CO)-CH(NH2)-$(CH2)_2$-COOH,



, whereby the phenyl can optionally be substituted in one or more places, the same or differently with halogen, C_{1-6}-alkyl or $-(CO)-C(CH_2)-C_2H_5$,

or represents C_3-alkinyl,

R^3 or R^4 in each case independently of one another represent hydrogen or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with hydroxy, phenyl or hydroxyphenyl,

or

R^3 and R^4 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupoted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the C_{3-6}-heterocycloalkylring can optionally be substituted with C_{1-6}-alkyl, C_{1-6}-alkyl-COOH or C_{1-6}-alkyl-NH2,

R^5 represents C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently with halogen, hydroxy, phenyl or with the group $–NH_2$, -NH(CO)-O-C_{1-6}-alkyl, whereby phenyl itself can optionally be substituted in one or more places, the same way or differently with halogen, hydroxy or C_{1-6}-alkyl,

R^6 represents C_{1-6}-alkyl, C_{2-6}-alkenyl or phenyl,

R^7 represents hydrogen or C_{1-6}-alkyl and

R^8or R^9 in each case independently of one another represent hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl, aryl or phenyl, whereby aryl or phenyl can optionally be substituted in one or more places, the same way or differently with hydroxy or the group $–NO_2$ or -N(C_{1-6}-alkyl)$_2$

or

R^8 and R^9 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby the C_{3-6}-heterocycloalkylring can optionally be substituted with the group $–NH_2$,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

7. (Currently Amended) Compounds of general formula (I) according to claim 1 ~~or 6~~ in which

A or B in each case independently of one another represent hydrogen or the group -NH-C_2H_4-OH, -NH-CH_2-hydroxyphenyl, -NH-(CO)-pyrrolidinyl, -NH-(CO)-$CH(NH_2)$-CH_2-phenyl, -NH-(CO)-pentyl-NH_2, -NH-(CO)-hexyl-NH_2, -NH-(CO)-CH_2-NH_2, -NH-(CO)-$CH(NH_2)$-hydroxyphenyl, -NH-(CO)-CH_2-hydroxyphenyl, -NH-(CO)-CH_2-methylphenyl, -NH-(CO)-C_2H_4-dihydroxyphenyl, -NH-(CO)-CH(OH)-phenyl, -NH-(CO)-$CH(NH_2)$-$CH_2(OH)$, -NH-(CO)-$C(CH_3)_2NH_2$, -NH-(CO)-$NH(C_2H_5)$, -CH_2OH, -(CO)-NH-cyclopropyl, -(CO)-NH-$CH(CH_3)_2$, whereby the pyrrolidinyl can optionally be substituted with hydroxy or the group –NH_2,

X represents an oxygen atom or the group –NH-,

R^1 represents halogen or hydroxymethyl and

R^2 represents –C_2H_5 optionally substituted in one or more places, the same way or differently with hydroxy, imidazolyl

or represents –C_3H_7 or –C_4H_8 optionally substituted in one or more places, the same way or differently with the group –NH_2, –NH-(CO)-$CH(NH_2)$-C_2H_4-COOH, -NH-(CO)-phenyl, –NH-(CO)-CH_2-phenyl, -NH-(CO)-CH_2-$CH(CH_3)$-phenyl, –NH-(CO)-CH_2-O-phenyl, –NH-(CO)O-CH_2-phenyl, -NH-(CO)-$CH(NH_2)CH_2$-phenyl,



whereby the phenyl can optionally be substituted in one or more places, the same or differently with halogen, $-CH_3$ or $-(CO)-C(CH_2)(C_2H_5)$,

or represents C_3-alkinyl,

as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

8. (Original) Compounds of general formula (I) according to claim 7,
N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
1-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
N-[3-[[5-bromo-4-[[3-[[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-p-tolyl-acetylamino)-propylamino]-

pyrimidin-2-ylamino}-phenyl)-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyryl)-phenoxy]-acetylamino}-propylamino)-pyrimidin-2-ylamino]-phenyl}-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyrylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,

N-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[(2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,

N-[3-[[(2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,

(α*R*)-α-Amino-*N*-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-(hydroxymethyl)phenyl]benzenepropanamide,

2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-ethanol,

(2R)-Amino-N-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,

3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)- N-cyclopropyl-benzamide,

3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)- N-isopropyl-benzamide,

Phenylmethyl [3-[[2-[[3-[[(ethylamino)carbonyl]amino]phenyl]amino]-5-(hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,

Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,
1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
2-{[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl}-phenol,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-propionamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-acetamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-acetamide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-propionamide,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-propionamide,
2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-propionamide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-

phenyl)-propionamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide or

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide.

9. (Original) Compounds of general formula (I) according to claim 1

in which

A or B in each case independently of one another represent halogen, hydrogen or the group $-SO_2-CH_3$, $-NO_2$, $-NH_2$, $-CF_3$, $-CH_2-NH-(CO)-NH_2$, -CH2-pyrrolidinyl, $-NH-(CO)-CH_3$, $-NH-(CO)-hexyl-NH_2$, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, $--NH-(CO)-CH(NH_2)-CH_2$-phenyl, $NH-(CO)-OCH_3$, $-NH-(CO)-OCH(CH_3)_2$, $-NH-(CO)-OC_2H_4$-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, $-NH-(CO)-NH-C_2H_4$-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl,

whereby the pyrrolidinyl can optionally be substituted with hydroxy or the group $-NH_2$ and

whereby the hydantoinyl can optionally be substituted with the group $-CH_3$ or -(CO)-thiazolidinonyl,

X represents the group –NH-,

R^1 represents halogen and

R^2 represents $-CH_2$-dihydroxyphenyl, $-C_2H_4$-imidazolyl, or $-C_3H_7$ optionally substituted in one or more places, the same way or differently with



as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts thereof.

10. (Original) Compounds of general formula (I) according to claim 7,

4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,

N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-urea,

1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-pyrrolidinol,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid methyl ester,

N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-cyclopropyl-urea,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 1-methylethyl ester,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-morpholinyl)ethyl)-urea,

N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 2-(4-morpholinyl)ethyl ester,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-hydroxycyclohexyl)-urea,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,

(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,

3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,

3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,

1-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

1-[3-[[2-[[3-[[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

3-[3-[[5-bromo-4-[[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,

3-[3-[[5-bromo-4-[[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-

methyl-2,4-imidazolidinedione,
(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
(4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[(4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide.

11. (Original) A compound of following structure
N-(3-((4-((3-(aminomethyl)phenyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidine-carboxamide,
4-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]- 1-naphthaleneacetic acid,
5-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indole-2-carboxylic acid, ethyl ester,
5-bromo-N4-[2-(1H-imidazol-5-yl)ethyl]-N2-(2-methyl-6-quinolinyl)-2,4-pyrimidinediamine,
4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1,3-dihydro-2H-benzimidazol-2-one,

3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

3-amino-5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

N-((3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-methanesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-phenol,

5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-*1H*-isoindole-1,3(2H)-dione,

5-bromo-N^4-(2-(*1H*-imidazol-4-yl)ethyl)-N^2-(3-methylphenyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-methyl-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((3-aminopropyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((3-(*1H*-imidazol-1-yl)propyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(1-pyrrolidinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid,

4-((4-((3-((aminocarbonyl)amino)propyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid ethyl

ester,
4-((5-bromo-4-((4-(methylamino)butyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
4-((5-bromo-4-((2-(*1H*-imidazol-1-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
4-((5-ethyl-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
4-((5-bromo-4-((2-(2-pyridinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
4-((5-bromo-4-((2-(*1H*-indol-3-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-acetamide,
N-(2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)ethyl)-acetamide,
3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-propanamide,
N-(4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)butyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-furancarboxamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-*1H*-pyrrole-2-carboxamide,
4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-thiophenecarboxamide,
4-((4-(4-(aminomethyl)-1-piperidinyl)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
4-(5-Brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-N,N-dimethylaminosulfonylamin,
1-Methyl-1H-imidazol-4-sulfonsäure [4-(5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-amid,
3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,

2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenol,
4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,
3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
2-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
Methyl 3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-[(2-hydroxyethyl)amino]benzoate,
Methyl 3-amino-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]benzoate or
3-[Bis-(2-hydroxy-ethyl)-amino]-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester.

12. (Currently Amended) Pharmaceutical composition comprising as an active ingredient at least one compound ~~of general formula (I)~~ according to claim 1 ~~any one of claims 1 to 10 or compounds according to claim 11~~ in an therapeutically effective amount for the prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis together with an pharmaceutically acceptable carrier, diluent or excipient.

13. (Currently Amended) Use of a compound ~~of general formula (I)~~ according to claim 1 ~~or 10 or compounds according to claim 11~~ for the manufacture of a medicament for the prevention or treatment of a disorder caused by, associated with or accompanied by any abnormal kinase activity selected from Chk, Akt, Pdk, Cdk and/or VEGF-R activity as well as combinations thereof.

14. (Currently Amended) The use of a compound of general formula (I) according to claim 1 ~~any one of claims 1 to 5~~, wherein the kinase is selected from PDK1, Akt1, Akt2 and/or Akt3.

15. (Original) The use of a compound of general formula (I) according to claim 13, wherein the kinase is selected from PDK1, Akt1, Akt2 and/or Akt3 in combination with VEGF-R.

16. (Currently Amended) The use of a compound of general formula (I) according to claim 1 ~~any one of claims 1 and 6 to 8~~, wherein the kinase is selected from Chk1 and/or Chk2.

17. (Currently Amended) The use according to claim 13 ~~any one of claims 13 to 16~~, wherein the disorder is selected from cancer, angiofribroma, arthritis, eye diseases, auto-immune diseases, chemotherapy agent-induced alopecia and mucositis, Crohn-disease, endometriosis, fibrotic diseases, hemangioma, cardiovaskular diseases, infectious diseases, nephrological diseases, chronic und acute neurodegenerative diseases, like disruptions of nerval tissue, viral infections, to prevent restenosis of vessels, for preventing the formation of scars, preventing or treating keratoma seniles and contact dermatitis.

18. (Original) The use according to claim 17, wherein
cancer stands for solide tumours, tumour- or metastasis growth, Kaposis Sarkom, Hodgkin's disease and/or leukemia,
arthritis stands for rheumatoid arthritis,
eyes diseases stand for diabetic retinopathy, neovaskular glaukoma,
auto-immune diseases stand for psoriasis, alopecia and/or multiple sklerosis,
fibrotic diseases stand for cirrhosis of the liver, mesangial cell proliferative diseases, arteriosklerosis,
infectiouse diseases stand for diseases that are caused by unicellular parasites,
cardiovascular diseases stand for stenosis, like stent induced restenosis, arteriosklerosis and restenosis,
nephrological diseases stand for glomerulonephritis, diabetic nephropaty, malignant nephrosklerosis, thrombic mikroangiopathis syndrome, transplant rejections and glomerulopathy,
chronic neurodegenerative diseases stand for Huntington's disease, amyotrophic

lateralsklerosis, Parkinsons disease, AIDS, dementia und Alzheimer's disease, acute neurodegenerative diseases stand for ischemias of the brain and neurotraumas, and viral infections stand for cytomegalic infections, herpes, hepatitis B or C and HIV.

19. (Currently Amended) A method of treating a mammal having a disease-state alleviated by the inhibition of Akt, Pdk, chk and/or VEGF-R activity, wherein the method comprises administering to a mammal a therapeutically effective amount of a compound ~~of general formula (I)~~ according to claim 1 ~~any one of claims 1 to 10 or the compounds of claim 11~~.

20. (Original) The method of claim 19 wherein the mammal is a human.

21. (Currently Amended) The method of claim 19 ~~or 20~~, wherein the disease-state is cancer, angiofribroma, arthritis, eye diseases, auto-immune diseases, chemotherapy agent-induced alopecia and mucositis, Crohn's disease, endometriosis, fibrotic diseases, hemangioma, cardiovaskular diseases, infectious diseases, nephrological diseases, chronic und acute neurodegenerative diseases, like disruptions of nerval tissue, viral infections, prevention of restenosis of vessels, prevention the formation of scars, prevention or treatment of keratoma seniles or contact dermatitis.

22. (Original) The method of claim 21, wherein
cancer stands for solide tumours, tumour- or metastasis growth, Kaposis Sarkom, Hodgkin's disease and/or leukemia,
arthritis stands for rheumatoid arthritis,
eyes diseases stand for diabetic retinopathy, neovaskular glaukoma,
auto-immune diseases stand for psoriasis, alopecia and/or multiple sklerosis,
fibrotic diseases stand for cirrhosis of the liver, mesangial cell proliferative diseases, arteriosklerosis,
infectiouse diseases stand for diseases that are caused by unicellular parasites,
cardiovascular diseases stand for stenosis, like stent induced restenosis, arteriosklerosis and

restenosis,

nephrological diseases stand for glomerulonephritis, diabetic nephropaty, malignant nephrosklerosis, thrombic mikroangiopathis syndrome, transplant rejections and glomerulopathy,

chronic neurodegenerative diseases stand for Huntington's disease, amyotrophic lateralsklerosis, Parkinsons disease, AIDS, dementia und Alzheimer's disease,

acute neurodegenerative diseases stand for ischemias of the brain and neurotraumas, and

viral infections stand for cytomegalic infections, herpes, hepatitis B or C and HIV.

23. (New) Pharmaceutical composition comprising as an active ingredient at least one compound according to claim 11 in an therapeutically effective amount for the prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis together with an pharmaceutically acceptable carrier, diluent or excipient.

24. (New) Use of a compound according to claim 11 for the manufacture of a medicament for the prevention or treatment of a disorder caused by, associated with or accompanied by any abnormal kinase activity selected from Chk, Akt, Pdk, Cdk and/or VEGF-R activity as well as combinations thereof.

25. (New) A method of treating a mammal having a disease-state alleviated by the inhibition of Akt, Pdk, chk and/or VEGF-R activity, wherein the method comprises administering to a mammal a therapeutically effective amount of a compound according to claim 11.